I mentioned that when Canada announced that it would be the first to implement the legislation, immediately we spoke with our colleagues. As I said, we are in many countries. We decided that we would try to use it, for a couple reasons: first, to see if it's workable, and second.... We don't think Canada is going to solve the access to medicine crisis, but it can contribute. We've seen the effect of generic competition, so another generic is excellent.
We thought Canada could also play a part, as I mentioned, with second-line medicines, with innovation, with new medicines, and with pediatric formulations. So we did see a role for Canada. We spoke about it internationally in our programs. We had a lot of endorsement from our field teams working in these 30 countries.
I think it's so important to reiterate that the changes that can be made can make it less complex and can make it work. But the way it is now, no country wants to take it up. If it's simplified and if it really follows the WTO paragraph 6 idea to allow generic competition, to allow export of generic medicine to developing countries, this can really contribute.
You speak about competition. Well, India right now, we know, is producing many of the generics, but that's at risk. So we need more solutions, and Canada can be in that.